Blue Ridge Mental Health

Obsessive-compulsive disorder (OCD)](/ocd) is one of the most treatable conditions in psychiatry — but only when it is treated correctly. The same class of medications used for depression and anxiety is also used for OCD, but that is where the similarities end. OCD requires different medications, different doses, and different timelines. When OCD is treated like anxiety or depression, effective medications get prescribed at the wrong dose, abandoned too early, or never tried at all — and patients are told that “medication doesn’t work” when the right medication was never given a fair chance.

At Blue Ridge Mental Health, OCD is a flagship specialty. The practice provides evidence-based grounded in current clinical guidelines, anti-obsessional dosing strategies, and close coordination with ERP therapists.

OCD Medication Management Requires a Different Approach

OCD and anxiety disorders like generalized anxiety disorder (GAD) are different conditions with different neurobiology. Although OCD was historically classified as an anxiety disorder, it is now recognized as a distinct condition with its own diagnostic category, its own brain circuitry, and its own evidence-based treatment recommendations. That distinction matters because many medications that work well for anxiety have little or no evidence for treating OCD — and some can even interfere with recovery.

This means OCD has its own medication toolkit. Understanding what belongs in that toolkit — and what does not — is the foundation of specialized OCD medication management. The table below shows the two toolkits side by side.

The only overlap in first-line treatments is SSRIs — and even there, OCD requires different doses and longer treatment timelines. Beyond SSRIs, the two toolkits have almost nothing in common.

The Right Medication

The evidence-based sequence for OCD medication management works through the first-line medications before moving to augmentation:

– SSRI #1 at anti-obsessional doses for a minimum of 12 weeks

– SSRI #2 at anti-obsessional doses for a minimum of 12 weeks

– Clomipramine (Anafranil) at anti-obsessional doses for a minimum of 12 weeks

– Augmentation strategies added to an adequate SSRI/SRI trial

At every step, medication should be combined with [Exposure and Response Prevention (ERP) therapy](/erp) for the best outcomes.

For a detailed comparison of the two toolkits and how OCD augmentation strategies work, see [OCD Medication vs. Anxiety Medication: Two Different Toolkits](/ocd-medication-vs-anxiety-medication-two-toolkits).

The Right Dose

Even when the right medication is prescribed, the doses used for depression and anxiety are too low to produce an anti-obsessional effect. OCD requires anti-obsessional doses — and these are the standard of care in specialized OCD treatment.

A dose of sertraline that works well for depression — anywhere from 50 to 200 mg — may do very little for OCD. The anti-obsessional target for sertraline is 400 mg. This pattern holds across all SSRIs used for OCD. There are depression and anxiety doses, and there are anti-obsessional doses. They are not the same.

Anti-obsessional doses are sometimes called “supratherapeutic” or “high-dose,” but those terms are misleading. They come from the world of depression treatment. For OCD, anti-obsessional doses are the therapeutic doses — the doses the condition actually requires. Evidence-based guidelines recommend these doses as the standard of care for OCD.

The Right Amount of Time

OCD also responds to medication on a different timeline than depression or anxiety. When SSRIs are prescribed for depression, improvement often begins within two to four weeks. OCD does not follow that timeline. Evidence-based guidelines recommend a full 12 weeks at anti-obsessional doses before concluding that a medication trial has been ineffective.

This means 12 weeks at the anti-obsessional target dose — not 12 weeks from the day the prescription was written. The weeks spent gradually increasing the dose do not count toward the trial. Augmentation strategies need at least 8 weeks at an appropriate dose before determining whether they are effective.

False Failures and the Myth of Treatment Resistance

When the right medication is not prescribed, or the right dose is not reached, or the right amount of time is not given — the medication appears to fail. But it did not fail. It was never given a fair chance. This is a false failure.

False failures create a pattern. A patient tries an SSRI at a dose that works for depression, does not improve after a few weeks, and the prescriber concludes the medication did not work. Another medication is tried under the same conditions. Same result. After several rounds of this, the patient is told they are “treatment-resistant.” But they have never received a single adequate OCD medication trial — the right medication, at the right dose, for the right amount of time.

The result is a patient who has been on multiple medications — sometimes for years — without ever receiving the kind of treatment that OCD actually requires.

Where Non-Specialists Go Wrong

When a prescriber is not familiar with OCD-specific evidence-based guidelines, two things tend to happen.

First, they use the wrong first-line treatments. Instead of working through SSRIs and clomipramine at anti-obsessional doses, they reach for what they know — the GAD toolkit. They prescribe medications that have no evidence for treating OCD, or they prescribe the right medication at the wrong dose for the wrong duration.

Second, they use the wrong augmentation strategies. When an underdosed SSRI does not produce results, they augment with GAD augmentation strategies — adding buspirone or mirtazapine to an SSRI that was never brought to anti-obsessional doses. These combinations have no evidence for treating OCD. OCD has its own augmentation strategies — serotonergic, glutamatergic, and antipsychotic augmentation — and they are added to an adequate SSRI/SRI trial, not used in place of one.

A specialist who understands OCD-specific evidence-based guidelines knows which medications to use, at what doses, for how long, and what to do when the first approach is not enough.

Working With ERP Therapists

Medication management is one component of comprehensive OCD treatment. is the gold-standard psychotherapy for OCD, and combined treatment — medication plus ERP — consistently produces the best outcomes. Medication reduces the intensity and severity of symptoms. ERP teaches new responses to obsessive thoughts. They work through different mechanisms, and together they produce results that neither achieves as effectively alone.

At Blue Ridge Mental Health, collaboration with ERP therapists is a core part of the treatment model. The clinical team coordinates directly with therapists to ensure that medication management and therapy are working together — including adjusting medication timing and dosing to support the therapy process.

One important consideration: as-needed medications such as benzodiazepines, hydroxyzine, and propranolol can interfere with ERP. These medications reduce distress in the moment, but in OCD treatment, learning to tolerate distress is how recovery happens. Using one of these medications during exposures can function as a safety behavior, preventing the new learning that ERP depends on.

Patients who are not currently working with an ERP therapist are welcome — medication management can begin while a therapist referral is being arranged, and the practice can help connect patients with ERP providers.

OCD Is a Chronic Condition — Maintenance Treatment Matters

OCD is a chronic condition with episodic flare-ups, and for most people, ongoing medication is recommended. Relapse rates are as high as 80% when medication is discontinued after short treatment periods of less than one year, compared to as high as 40% after two or more years of treatment. If a decision is made to try reducing medication, it should be done very gradually and ideally with the support of ERP therapy to reduce the risk of relapse.

Signs Your OCD May Not Be Getting the Right Medication Treatment

If any of the following sound familiar, it may be worth seeking a consultation with a clinician who specializes in OCD. Compare current medications to the toolkit table above:

– Current medications are from the GAD toolkit rather than the OCD toolkit

– An SSRI was tried but never reached anti-obsessional doses

– A medication was changed after less than 12 weeks at the target dose

– Multiple medications were tried in rapid succession without any reaching an adequate dose for an adequate duration

– No one has discussed anti-obsessional dosing, the 12-week trial, or OCD-specific augmentation strategies

Take the Next Step

If unwanted intrusive thoughts, compulsions, reassurance seeking, mental reviewing, or persistent doubt is interfering with your daily life, Blue Ridge Mental Health provides specialized virtual psychiatric care for OCD and OC-related disorders.

We provide virtual OCD care for patients in Alaska, Arizona, Arkansas, Florida, Illinois, Indiana, Maine, New York, North Carolina, Ohio, Virginia, and Washington, D.C.

Contact our team to learn more about OCD evaluation and medication management or to discuss collaborative care with your existing ERP therapist.

This article is for education and is not individual medical advice. If you are in crisis or feel unsafe, call or text 988 in the U.S. or go to the nearest emergency room.

Frequently Asked Questions

Why is OCD medication management different from treating anxiety?

OCD and anxiety disorders involve different neurobiology and respond to different medications. Anxiety disorders respond to a wide range of medications. OCD responds specifically to SSRIs and clomipramine at anti-obsessional doses, with its own augmentation strategies when first-line treatment is not sufficient. Treating OCD with the anxiety toolkit is one of the most common reasons the condition goes undertreated.

What does the first appointment look like?

The first appointment is a comprehensive psychiatric evaluation — typically 60 minutes. It covers current symptoms, OCD subtypes, treatment history including all previous medication trials with doses and durations, co-occurring conditions, and goals for treatment. The evaluation is conversational and thorough, designed to understand the full picture before making any treatment recommendations.

What if I have already tried medication and it did not work?

Many patients arrive after previous medication trials that were not conducted at anti-obsessional doses or were not continued long enough to assess effectiveness. A detailed review of past trials — including specific medications, doses, and durations — is part of every evaluation. There are well-established next steps for patients who have not responded to initial treatment, including dose optimization, medication switches, and evidence-based augmentation strategies.

Can I continue seeing my current therapist?

Yes. Blue Ridge Mental Health welcomes collaboration with existing therapists and treatment teams. Coordinated care — particularly with ERP therapists — is a core part of the treatment model.

Do you accept insurance?

Yes. Blue Ridge Mental Health accepts most major commercial insurance plans, and in select states, Medicare and Medicaid.

Getting the Right OCD Medication Management

OCD is treatable — but it requires the right medication, at the right dose, for the right amount of time, with the right augmentation strategies when needed, and in coordination with ERP therapy. At Blue Ridge Mental Health, OCD medication management is built around these principles — evidence-based guidelines, anti-obsessional dosing, adequate trial durations, OCD-specific augmentation, and close collaboration with ERP therapists. Whether this is a first medication trial or a next step after previous treatment has not been enough, the practice provides the kind of focused, specialized care that OCD requires.

References

1. Goodman WK, Storch EA, Sheth SA. Harmonizing the Neurobiology and Treatment of Obsessive-Compulsive Disorder. Am J Psychiatry. 2021;178(1):17-29.
2. Grant JE. Obsessive-Compulsive Disorder. N Engl J Med. 2014;371(7):646-653.
3. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder. Arlington, VA: American Psychiatric Association; 2007.
4. Hirschtritt ME, Bloch MH, Mathews CA. Obsessive-Compulsive Disorder: Advances in Diagnosis and Treatment. JAMA. 2017;317(13):1358-1367.
5. Borue X, Sharma M, Hudak R. Biological Treatments for Obsessive-Compulsive and Related Disorders. J Obsessive Compuls Relat Disord. 2015;6:7-26.
6. Mao L, Hu M, Luo L, et al. The Effectiveness of Exposure and Response Prevention Combined With Pharmacotherapy for Obsessive-Compulsive Disorder: A Systematic Review and Meta-Analysis. Front Psychiatry. 2022;13:1003113.
7. Kishi T, Sakuma K, Hatano M, et al. Relapse Rates in Stable Obsessive-Compulsive Disorder After Antidepressant Discontinuation Versus Maintenance: A Systematic Review and Meta-Analysis. Psychol Med. 2025.
8. Semenya AM, Bhatnagar P. Diagnosis and Management of Obsessive-Compulsive Disorder in the Primary Care Setting. Am Fam Physician. 2024;110(4):393-400.